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Abstract Mucopolysaccharidosis II (MPS II), or Hunter
syndrome, is an X-linked lysosomal storage disorder caused
by a deficiency in the enzyme iduronate-2-sulfatase. Affect-
ed patients suffer progressive damage to multiple organ
systems and early mortality. Two thirds of patients also
manifest cognitive impairment and developmental delays.
MPS II can be extremely difficult to diagnose before irre-
versible organ and tissue damage has occurred because of an
insidious onset and the overlap in signs and symptoms with
common childhood complaints. This is particularly true of
patients without cognitive impairment (attenuated pheno-
type). Although not curative, early treatment with enzyme
replacement therapy before irreversible organ damage has
occurred may result in the greatest clinical benefit. Here, the
signs, symptoms, and surgical history that should trigger
suspicion of MPS II are described, and the diagnostic pro-
cess is reviewed with a focus on practical considerations and
the avoidance of common diagnostic pitfalls. Once a diag-
nosis is made, multidisciplinary management with an ex-
tended team of pediatric specialists is essential and should
involve the pediatrician or family practice physician as
facilitator and medical home for the patient and family.
Conclusion: Because routine newborn screening is not yet
available for MPS II, the involvement and awareness of
pediatricians, family practice physicians, and pediatric spe-
cialists is critical for early identification, diagnosis, and
referral in order to help optimize patient outcomes.
Keywords Lysosomalstoragedisease.
MucopolysaccharidosisII.Hunter syndrome.
Glycosaminoglycans.Iduronate-2-sulfatase.Diagnosis
Abbreviations
ERT Enzyme replacement therapy
GAG Glycosaminoglycan
I2S Iduronate-2-sulfatase
LSD Lysosomal storage disease
MPS Mucopolysaccharidosis
Introduction
The mucopolysaccharidoses (MPS) are a group of rare
genetic disorders within the larger family of lysosomal
storage diseases (LSDs). Each MPS disorder is caused by
a deficiency in the activity of a specific lysosomal enzyme
required for the degradation of glycosaminoglycans
(GAGs). The resulting accumulation of GAGs within lyso-
somes produces progressive cellular damage, leading to
organ failure and reduced life expectancy [32].
Mucopolysaccharidosis II (MPS II or Hunter syndrome;
OMIM 309900) is an X-linked disorder with an incidence of
0.3 to 0.71 per 100,000 live births [24]. It is a caused by a
deficiency in the lysosomal enzyme iduronate-2-sulfatase
(I2S), leading to an accumulation of the GAGs dermatan
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DOI 10.1007/s00431-012-1703-ysulfate and heparan sulfate [2]. The consequence of GAG
accumulation is progressive, multi-organ disease (Tables 1
and 2).
MPS II is characterized by clinical heterogeneity in that
the number and type of presenting signs and symptoms can
vary widely among patients. It is often described as having
two phenotypes: attenuated and severe. Patients with either
phenotype generally appear normal at birth. In patients with
the severe phenotype, clinical signs and symptoms (Tables 1
and 2) usually emerge between 2 and 4 years of age [47],
whereas in those with the attenuated phenotype, signs and
symptoms may not emerge until late childhood or early
adolescence [48]. Patients with attenuated and severe dis-
ease both experience significant somatic signs and symp-
toms, but patients with severe disease also have profound
cognitive impairment and developmental regression [49, 50]
which is not seen in the attenuated phenotype. Life expec-
tancy is also shorter in patients with severe disease, with
death typically occurring in the second decade of life [15].
Patients with the attenuated phenotype may survive into
adulthood, although premature mortality does occur [15].
It is important to note that although patients with attenuated
disease do not experience cognitive impairment, they may
still demonstrate all of the somatic signs and symptoms of
the disease, including neurological complications such as
communicating hydrocephalus, spinal cord compression,
and hearing loss [24].
Historically, treatment for MPS II has been supportive;
however, enzyme replacement therapy (ERT) with idursul-
fase, a recombinant human I2S enzyme (Elaprase®, Shire
Human Genetic Therapies, Inc., Cambridge, MA), is now
available in more than 40 countries. In a phase II/III clinical
trial enrolling children over the age of 5 years, idursulfase
was shown to improve some of the somatic signs and
symptoms of the disease, including walking ability, al-
though it does not affect the cognitive decline seen in
patients with severe disease [29]. The most common adverse
events are infusion reactions, such as fever, flushing, rash,
or headache. Life-threatening anaphylactic reactions have
occurred in patients receiving ERT. A clinical trial of idur-
sulfase for the treatment of MPS II patients aged 5 years and
under is currently ongoing.
Early initiation of ERT may offer the greatest benefit [28,
38], but there is often a delay of several years between the
onset of signs and symptoms and diagnosis. This is partic-
ularly true for patients with the attenuated phenotype, as the
disease onset can be insidious (see Case study: patient D).
Such delays increase the risk of irreversible organ damage
and may decrease the benefit of ERT [28, 43, 47]. Because it
is the pediatrician or family practice physician who often
recognizes the existence of a deeper problem, increased
awareness of MPS II is a critical factor in early diagnosis,
referral, and treatment. The recently published European
recommendations for the management of MPS II note that
expertise in diagnosis and managing MPS II varies widely
throughout Europe [37]. The authors highlight the need for
guidance on how to recognize and diagnose this disorder. A
previous review offers an excellent overview of the disease
for the reader who is unfamiliar with MPS II [24]. Here, we
focus on the practical considerations of diagnosing this
syndrome in the busy pediatric practice by describing “red
flags” in the patient history, suspicious signs and symptoms,
and common diagnostic pitfalls to avoid. We discuss the
available laboratory tests and whether or not they can be
relied upon to confirm or rule out the diagnosis, and outline
the differential diagnoses. We conclude with a diagnostic
algorithm specifically tailored for the pediatric general
practice.
Clinical suspicion of MPS II
Early recognition of MPS II requires careful attention to the
presence of multiple signs and symptoms, many of which
overlapwith common childhood complaints.Clinicalsuspicion
of the disease can be triggered by particular clusters of signs
and symptoms that are unlikely to appear in an unaffected child
but that often occur together in the child with MPS II (Table 1).
Most of the common somatic manifestations that occur early in
the disease course appear in both the attenuated and severe
phenotypes, although theymay be more subtle in the attenuated
phenotype [24]. Coarse facial features are a strong diagnostic
clue of an LSD and are manifest in MPS II patients with
varying disease severity (Figs. 1 and 2). Ear, nose, and throat
signs and symptoms include recurrent respiratory infections,
chronic rhinorrhea, upper airway obstruction, noisy breathing
and snoring, hearing loss, and recurrent otitis media [16, 31].
SomechildrenwithMPSIIwillhaveadetectableheartmurmur
relatively early in the disease course [7]. Common abdominal
complaints include hepatomegaly, umbilical and inguinal
Table 1 “Red Flag” signs and symptoms of MPS II that occur early in
the disease course
Coarse facial features (may be subtle in the attenuated phenotype)
Recurrent respiratory infections
Chronic rhinorrhea
Upper airway restriction/noisy breathing/snoring
Recurrent otitis media
Hearing loss
Heart murmur
Hepatomegaly
Umbilical and inguinal hernia
Recurrent watery diarrhea
Joint stiffness
Developmental delay and/or speech delay (in severe phenotype only)
632 Eur J Pediatr (2012) 171:631–639hernias without family history of hernia, and recurrent episodes
of diarrhea [24]. These episodes of watery diarrhea are
frequently observed in the MPS II population, although the
underlying pathophysiology is not understood. The diarrhea is
often very difficult for the family to manage and is resistant to
medication. Early skeletal signs include joint stiffness and
Table 2 Signs and symptoms of MPS II and clinically similar LSDs
Sign/symptom MPS II MPS I MPS
III
MPS
VI
MPS
VII
Sialidosis
type 2
Mucolipidosis
II alpha/beta
Mucolipidosis
III alpha/beta
Alpha-
mannosidosis
Coarse facial features ++ ++ + ++ ++ ++ ++ + ++
Macrocephaly ++ ++ + ++ ++ ++ −− ++
Communicating
hydrocephalus
++ − ++ − ++ + + +
Dental abnormalities ++ + − ++ ++ − ++ − ++
Cognitive/developmental
delay
++ + + − ++ ++ ++ + ++
Severe patients
only
Severe patients
only
Spinal cord compression + + − ++ − ++ +−
Carpal tunnel syndrome ++ ++ − ++ ++ − ++ +−
Hyperactivity, aggression,
impulsivity
+ − ++ −− − − − −
Seizures + − + −− ++ −−−
Hearing loss ++ ++ + ++ ++ ++ ++ ++ ++
Recurrent ear infections ++ ++ + ++ ++ − ++ ++ ++
Persistent rhinorrhea ++ ++ + ++ ++ −− − −
Frequent respiratory
infections
++ ++ + ++ ++ − ++ ++ ++
Respiratory obstruction ++ ++ − ++ ++ − ++ −−
Sleep apnea ++ ++ + ++ ++ − ++ −−
Hepatosplenomegaly ++ ++ + ++ ++ ++ ++ ++ ++
Umbilical hernia/inguinal
hernias
++ ++ + ++ ++ ++ ++ ++ −
Chronic diarrhea ++ + + −− − − − −
Dysostosis multiplex ++ ++ + ++ ++ ++ ++ ++ ++
Growth retardation ++ ++ − ++ ++ ++ ++ ++ ++
Claw hands ++ ++ − ++ ++ − ++ ++ +
Joint stiffness/contractures ++ ++ + ++ ++ − ++ ++ ++
Cardiac valve disease ++ ++ + ++ ++ − ++ ++ −
Corneal clouding − ++ − ++ ++ ++ ++ ++ −
“++” Exhibited by majority of patients with diagnosis, “+” exhibited by some patients with diagnosis, “−” not exhibited
Fig. 1 Coarse facies in a 5-year-old child with MPS II. Note the
frontal bossing, heavy eyebrows, puffy eyes, broad “saddle” nose,
large jowls, thick lips, and enlarged tongue
Fig. 2 Patient D (attenuated phenotype) at 13 years of age. Note that
the coarse facies are more subtle than seen in patients with the severe
phenotype
Eur J Pediatr (2012) 171:631–639 633restricted range of motion [19]. Evidence of dysostosis multi-
plex can usually be seen on X-ray (Fig. 3). Although by later in
childhood patients with MPS II have growth restriction and
short stature, it is important to point out that in early childhood,
children withMPSII oftengrowfaster than normal. Height and
weight may be near or over the top of the standard growth
curves. The slowing in growth that is associated with the
disease only begins at around 3 to 4 years of age [36].
The presence of several of these somatic signs or symptoms
should prompt suspicion of MPS II. Keep in mind that most
patients do not display all of them early in the disease course,
and manifestations like coarse facial features may be very
subtle (Fig. 2). In addition to somatic signs and symptoms,
patients with the severe phenotype will begin to display devel-
opmental delay and/or speech delay between the ages of 2 to
5y e a r s[ 47] and will eventually progress to severe neurological
and cognitive decline by the second decade of life [49, 50].
A history of frequent and recurrent surgeries is a defining
characteristicofMPSIIandmayalsotriggerclinicalsuspicionof
thedisease.Astudythatanalyzedsurgicaldatafrom 527patients
with MPS II found that surgical interventions were performed in
83.7%, with a median number of 3.0 operations per patient [26].
The median age at first operation was 2.6 years, and most
patients (57%) underwent at least one surgical procedure before
diagnosis. Tympanostomies, repairs of inguinal hernias, and
operations for carpal tunnel syndrome were performed in a
greater proportion of the study population than the general
population. Thus, repeated early surgeries of these types should
serve as a clinical “red flag,” prompting careful examination for
other features of MPS and appropriate diagnostic testing.
Avoiding pitfalls
A common pitfall when examining the patient with undiag-
nosedMPSIIisafailuretolinkthemany,seeminglyunrelated
signs and symptoms experienced by the patient into a single
syndrome. This may be particularly challenging in cases of
attenuated MPS II in which the onset of disease signs and
symptomsis insidious,facialdysmorphismsmay bemild,and
no developmental delay is seen (see Case study: patient D).
Fig. 3 Skeletal manifestations
of MPS II: a 33° scoliosis with
coarseness of the bones and
widening of the ribs in a 16-
year-old patient with attenuated
MPS II; b magnetic resonance
imaging demonstrating mild
thoracolumbar kyphosis and
typical anterior vertebral body
deficiency in a 16-year-old
patient with attenuated MPS II;
c significant thoracolumbar
kyphosis in a 4-year-old patient
with severe MPS II; d caput
valgum and mild femoral head
uncoverage in a 9-year-old
patient with severe MPS II; e
J-shaped sella in a 21-month-
old patient with MPS II; f
severe delay in maturation
compatible with 3–6 months of
age, mild proximal tapering of
the metacarpals, and minimal
slenderness of the distal
phalanges in a 21-month-old
patient with MPS II. Images
a–d reproduced with
permission from White et al.
[45]
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ing too heavily upon exact diagnoses of LSDs in the family
history. In the past, LSDs were often diagnosed clinically. It
was not uncommon for MPS disorders to be lumped togeth-
er as “Hurler syndrome”, which we now know to be the
severe phenotype of MPS I. A family history of “Hurler
syndrome” or other MPS disorder should not rule out testing
for MPS II if warranted by findings on examination. The
authors are aware of several cases where a family history of
“Hurler syndrome” in an uncle or other male relative has
delayed the diagnosis of MPS II in an affected child.
Case study: patient D
Patient D, a Caucasian male, was born at full term with no
abnormal signs and symptoms. At 10 weeks of age, the
pediatrician diagnosed bilateral inguinal hernias which were
repaired surgically. Throughout the patient's first 5 years of
life, he presented with chronic watery diarrhea, frequent
upper respiratory infections, and repeated bouts of acute
otitis media that required antibiotic treatment. No develop-
mental or motor delays were noted. The parents would, on
occasion, express their concerns that something was
“wrong” with the child, but each time the parents were
reassured that everything was fine. By 5 years of age, patient
D was beginning to show some very mild facial dysmor-
phisms, and his growth began to slow. He also showed some
lack of flexibility in the upper body. The parents again
raised their concerns that something was amiss, but again
the pediatrician reassured them. Over the next 3 years,
patient D's growth slowed considerably and his range of
motion was further limited. He was also diagnosed with
moderate hearing loss and received a hearing aid. Because
of his range-of-motion deficits and slow growth, the pedia-
trician referred the patient to a pediatric orthopedist. The
orthopedist noted the child's stiff joints, slow growth, short
stature, mild facial dysmorphisms, hearing loss, and history
of frequent respiratory infections, and he suspected an MPS
disorder. The orthopedist referred the patient to a clin-
ical geneticist, and laboratory tests confirmed the diag-
nosis as MPS II. The child was 8 years old at the time
of diagnosis (Fig. 2), despite the fact that signs and
symptoms of MPS II were present as early as the first
months of life.
MPS II in females
A diagnosis of MPS II cannot be ruled out based on
female sex. Unlike the other X-linked LSDs (Fabry
disease, Danon disease), females carrying one mutated
allele of the gene that codes for I2S (IDS)a r e ,i n d e e d ,
usually asymptomatic. However, because MPS II has
been documented in a few females, MPS II should not
be ruled out based on sex or inheritance patterns alone.
Most commonly, symptomatic MPS II in females occurs
through skewed X-chromosome inactivation, in which
the mutated allele of IDS is preferentially activated
and the normal allele is inactivated [41]. It can also
be observed in females with a 45,X karyotype or with
an X-chromosome rearrangement, so chromosome anal-
ysis should always be performed in a female with a
confirmed diagnosis of MPS II. Females with this dis-
order typically present with a severe phenotype [41].
Biochemical and genetic explanations have been
reviewed by Pinto et al. [34].
Differential diagnosis
Key“redflag”signsandsymptomsofMPSIIarepresentedin
Table 1. However, because MPS II can present on a spectrum
of severity with variable signs and symptoms, the differential
diagnosis based on clinical features can be very challenging.
For example, several LSDs share features with MPS II
(Table 2); these include MPS I (Hurler syndrome) [30], MPS
VI (Maroteaux–Lamy syndrome) [42], MPS VII (Sly syn-
drome) [32], sialidosis type 2 [14], mucolipidosis II alpha/
beta [3], mucolipidosis III alpha/beta [3], and α-mannosidosis
[22]. The LSDs fucosidosis [46] and multiple sulfatase defi-
ciency [11] also share signs and symptoms with MPS II,
although these two disorders are extremely rare. Because so
many clinical features are shared among these LSDs, labora-
tory testing is necessary when clinical suspicion of an MPS
disorder has been raised.
Laboratory diagnostic testing for MPS II
A common diagnostic algorithm for MPS II is presented in
Fig. 4. Importantly, patients with MPS-like signs and symp-
toms should be promptly referred to a clinical geneticist
even if the standard diagnostic assays for MPS indicate
normal results. Further testing may be indicated to rule out
another LSD (Table 2).
Urinary GAG excretion
The level of urinary GAGs is increased in patients with any
MPS, so the detection of excessive urinary GAG excretion is
generally the first diagnostic approach, although patients with
a family history of MPS II should proceed directly to enzyme
activity assaysand/or moleculargenetic analyses[32]. Assays
canbedividedintosemiquantitative(theBerryspotandAmes
spot tests) and quantitative (the carbazole reaction, cetylpyr-
idiniumturbiditytest,alcianbluereaction,dimethylmethylene
blue test, and azure A and B method). Although simple and
Eur J Pediatr (2012) 171:631–639 635inexpensive, semiquantitative assays are not reliable due to a
relatively high rate of false positives and false negatives [8,
20] Improper reliance on semiquantitative assays alone thus
representsamajorpitfallinthediagnosticprocessfortheMPS
disorders. Among the quantitative assays, the carbazole reac-
tion has a low sensitivity for MPS IV (Morquio syndrome)
and the cetylpyridinium turbidity test has a low sensitivity for
MPS IVand MPS III (Sanfilippo syndrome); therefore, these
assays should be avoided [5, 35].
All samples should also be analyzed via thin layer chroma-
tography or one-dimensional or bidimensional electrophoresis
for the identification of an abnormal GAG pattern even if the
overalluGAG level is notelevated [24].Thepresenceof excess
dermatan sulfate and heparan sulfate in urine is indicative of
MPS I, MPS II, or MPS VII. Excess heparan sulfate alone
suggests MPS III, keratan sulfate alone suggests MPS IV, and
dermatan sulfate alone suggests MPS VI. However, as urinary
GAG assays are not diagnostic of a specific MPS, enzyme
activity assays must be performed to confirm the diagnosis.
It should be emphasized that a negative urinary GAG test,
even using a quantitative assay, does not necessarily rule out
the diagnosis of an MPS disorder. False-negative results may
occur due to dilute sample, variations in GAG excretion over
time, and overlap in ranges between affected and unaffected
patients. Mahalingam et al. quantitated urinary GAG levels in
91 healthy children and 219 children with MPS [21]. The
mean urinary GAG level was 2.5±2.09 mg/mmol creatinine
(range, 0.45–9.96) in the control group and 12.64±12.83 mg/
mmol creatinine (range, 0.5–78.4) in the MPS group. There-
fore, if clinical suspicion of MPS is high but the urinary GAG
level is normal, additional diagnostic testing should be pur-
sued (Fig. 4). Note also that urinary GAG testing cannot be
usedtodeterminetheMPSIIcarrierstatusofafemalebecause
the levels observed in carriers are typically within the range
observed in non-carrier females [39].
Enzyme activity
When urinary GAG levels are elevated, or if there is a strong
clinical suspicion of MPS II, enzyme activity testing should
be conducted. Although enzyme activity can be measured in
cultured fibroblasts, the standard samples are leukocytes,
plasma, or serum [44]. Enzyme assays based on the analysis
of dried blood spots are also being performed and are useful
in areas where it is difficult to collect and/or transport liquid
samples [6, 9]. Absent or very low I2S activity is diagnostic
of MPS II. A second sulfatase should also be measured in
the patient's sample to rule out multiple sulfatase deficiency,
an LSD that affects the entire sulfatase family [10].
Although enzyme assays are considered the gold standard
for diagnosis of MPS, they have several limitations. First,
there is no correlation between measurable I2S activity, as
Fig. 4 Diagnostic algorithm for
MPS II
636 Eur J Pediatr (2012) 171:631–639determined by routine diagnostic assays, and eventual
phenotype [33]. Second, enzyme activity is not reliable
for the identification of female carriers because of an
overlap in activity ranges between carrier and non-carrier
females [18, 39].
Genetic testing
Genetic testing of the IDS locus is the only reliable way to
identify female carriers of the disease, a critical factor in
family planning decisions [18]. To date, over 330 alterations
in the IDS gene have been reported in MPS II patients, many
of which are seen only within a single family [40]. Unfor-
tunately, the genetic heterogeneity associated with MPS II
and the private nature of many mutations present major
obstacles to genotype–phenotype correlation. Although un-
common, the MPS II phenotype can vary even among
family members who share the same IDS mutation [12]. It
is known that deletions or rearrangements of the IDS gene
that completely abolish I2S transcript production will result
in the severe phenotype. This information is valuable to
provide to families when it is available. The phenotypic
effects of other types of mutations are much more difficult
to predict.
Preimplantation genetic diagnosis and prenatal testing
Preimplantation genetic diagnosis for MPS II has been
reported in three Israeli families with successful outcomes
in all three, but this technique is not yet widely available [1].
Prenatal diagnosis via I2S enzyme assays or molecular
testing in chorionic villi or amniotic fluid cells is available
at some centers and can be offered to all couples with a
family history of MPS II to allow for informed decision
making about pregnancy termination [17]. Sex determina-
tion of the fetus is not adequate for a prenatal diagnosis,
given that a male offspring of a carrier mother has a 50%
chance of being unaffected.
Beyond family planning decisions, prenatal diagnosis
has also allowed for early initiation of ERT in other
forms of MPS, and sibling pair case-study data suggest
that the benefit of ERT was clearly greater in the sibling
treated from infancy than in the sibling treated as a
young child [25]. Similar conclusions about benefits of
early treatment have been reached for MPS II and early
treatment has been recommended in the recent European
guidelines [37]; however, this has not been evaluated in
clinical trials.
Choosing a laboratory for diagnostic testing
Clinicians should be aware that few laboratories perform
the diagnostic assays described above, and that values
can vary from laboratory to laboratory. The latter is
particularly true for urinary GAG testing [20]. Genetic
testing and prenatal testing for MPS II are not commonly
performed, so it is important to ensure that the laboratory
used is accredited and experienced in these analyses.
Listings such as GeneTests [27] may be helpful in this
regard.
Looking forward: newborn screening
The eventual goal for the early treatment of MPS II is
newborn screening; progress on this front has been reviewed
by Marsden and Levy [23]. Chamoles et al. [4] first dem-
onstrated that many lysosomal enzymes remain active in
dried blood spots and can be assayed after rehydration in a
suitable reaction buffer. Since that time, assays for lysosom-
al enzyme activity, including I2S activity, in dried blood
spots that may be suitable for newborn screening have been
developed [13]. Pilot population-based newborn screening
using any of these methods has not yet been reported. Until
newborn screening for MPS II becomes widespread, it
remains in the hands of aware and astute pediatricians,
family practice physicians, and pediatric specialists to rec-
ognize and refer patients with suspected MPS II as early as
possible.
After the diagnosis: multidisciplinary management
of MPS II
When a diagnosis of MPS II is confirmed or is strongly
suspected, prompt referral to a clinical geneticist is a
necessity in order to ensure timely treatment. Nonethe-
less, the pediatrician or family practice physician has a
key role to play in the multidisciplinary management of
the child with MPS II (reviewed by Muenzer et al. [28]).
Patients and caregivers are often overwhelmed with the
number of pediatric subspecialties that are involved in
care, including anesthesiology, cardiology, neurodevelop-
ment, neurosurgery, ophthalmology, orthopedics, otorhi-
nolaryngology, and pulmonology. Supportive services
such as physiotherapy, occupational therapy, speech ther-
apy, audiology, dentistry, and behavioral therapy are also
involved. The pediatrician or family practice physician
can help facilitate care among the many specialists the
family must interact with and can provide a consistent
medical home for the patient.
It is important to note that because of the airway
obstruction, pulmonary involvement, and spinal cord
compression associated with MPS II, any surgical or
screening procedures that require general anesthesia or
sedation should be performed only in a medical center
Eur J Pediatr (2012) 171:631–639 637that has extensive experience in handling children with
MPS II [31].
Conclusion
Mucopolysaccharidosis II is a rare genetic disorder that
affects multiple organ systems and reduces life expectancy.
Early diagnosis and referral are critical to help optimize
patient outcomes. ERT with recombinant human I2S en-
zyme is available, and early treatment may result in greater
clinical benefit, although more long-term data are needed to
fully assess the benefits of early treatment. A clinical trial in
patients under 5 years of age is currently ongoing. Clinical
suspicion of MPS II should be raised when a child presents
with a cluster of characteristic signs and symptoms or a
history of early and frequent surgeries. Not all patients with
MPS II will have all signs and symptoms, and severity can
vary widely. Urinary GAG testing is useful for screening,
although a negative result does not rule out MPS II. Diag-
nosis is confirmed by the measurement of I2S activity,
usually in blood. Genetic testing is the only reliable method
for carrier identification. If the standard diagnostic assays
are all within normal range but the child displays MPS-like
signs and symptoms, referral to a clinical geneticist is
strongly encouraged, as other genetic syndromes share fea-
tures with MPS II. Once a diagnosis is made, multidisci-
plinary management is critical and should involve the
pediatrician or family practice physician.
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